retatrutide biolongevity labs · Finnrick Peptides - hit or miss?

Growing Recognition of Obesity as a Chronic Disease: Obesity is increasingly being recognized as a chronic and multifactorial disease rather than solely a lifestyle condition

A possible increased risk of a specific type of thyroid cancer has not been confirmed in humans but requires caution in certain people

Many patients are on a combination of an SGLT2 inhibitor with a GLP-1 receptor agonist or tirzepatide (a dual agonist) and have incredible success without adverse reactions, but we are still figuring out the patient characteristics that would put them at higher risk of poor outcomes. Eli J

Users of Brand-Name GLP-1s Report Slightly Lower Effectiveness Users of brand-name GLP-1 medications report slightly lower effectiveness than do users of compounded or custom-mixed versions, but both types of patients consider the drugs to be effective